Quantcast
Last updated on April 18, 2014 at 13:06 EDT

Latest Camurus Stories

2014-03-24 16:24:27

DUBLIN, Mar. 24, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/xzvl54/nanotechnology_in ) has announced the addition of the "Nanotechnology in Drug Delivery - Global Strategic Business Report" report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769) This report analyzes the worldwide markets for Nanotechnology in Drug Delivery in US$ Million. The Global Market is further analyzed by the following Drug Delivery...

2014-01-20 23:02:53

GIA announces the release of a comprehensive global report on Nanotechnology in Drug Delivery markets. The global market for Nanotechnology in Drug Delivery is projected to reach US$53.3 billion by 2018, driven by aging population, rising incidence of chronic diseases, high unmet medical needs, and advancements in nanomedicine and nano drug delivery. San Jose, California (PRWEB) January 20, 2014 Follow us on LinkedIn – Pharmaceutical industry represents one of the early beneficiaries of...

2013-10-24 08:35:12

FRANKFURT, Germany, October 24, 2013 /PRNewswire/ -- API Corporation, E-Pharma Trento and Camurus- the 2013 winners The CPhI Pharma Awards 2013 winners were announced live at the awards ceremony- day one at CPhI Worldwide [http://www.cphi.com ]. Honouring outstanding developments from some key industry players, the awards highlighted ever-advancing market innovations, fundamental to driving growth throughout global pharma. (Logo:...

2013-09-10 04:22:07

LUND, Sweden, September 10, 2013 /PRNewswire/ -- Camurus announced today that Novartis has exercised its option to acquire an exclusive license for the further development and worldwide commercialization of CAM2029 for treatment of patients with acromegaly and neuroendocrine tumors (NETs). The license also covers additional future products based on the Camurus' FluidCrystal(R) Injection depot technology. (Logo:...

2010-12-08 06:03:00

WARREN, N.J. and OXFORD, England, Dec. 8, 2010 /PRNewswire/ -- MonoSol Rx, the developer of PharmFilm® drug delivery technology, and Midatech Group Ltd., a global leader and centre of excellence for the design, development, synthesis and manufacture of nanomedicines, today announced their intent to form a joint venture that will focus on the development and commercialization of products combining the two companies' respective technologies in the diabetes field....

2010-06-24 07:00:00

WARREN, N.J., June 24 /PRNewswire/ -- MonoSol Rx, the developer of PharmFilm® drug delivery technology, today announced the expansion of its agreement with Midatech Group (Oxford, UK) to develop nanoparticle-based proteins and peptides for therapeutic delivery utilizing pharmaceutical films. Under the terms of the expanded agreement, MonoSol Rx has made an equity investment in Midatech and Keith Kendall, Executive Vice President and Chief Financial Officer of MonoSol Rx,...

2010-06-09 07:03:00

WARREN, N.J. and BALERNA, Switzerland, June 9 /PRNewswire/ -- MonoSol Rx, the developers of PharmFilm® technology and a drug delivery company specializing in proprietary pharmaceutical film products, and APR Applied Pharma Research s.a. ("APR") announced today an expansion of their relationship to identify and develop film formulations of prescription drug products beyond ondansetron and donepezil to include zolmitriptan. Zolmitriptan is currently commercially available...

2008-10-20 09:00:41

Research and Markets (http://www.researchandmarkets.com/research/29d59e/whos_developing_w) has announced the addition of the "Who's Developing What in Drug Delivery?" report to their offering. The indispensable 2-volume guide to the companies that are shaping this critical area. The importance of drug delivery technology grows ever more acute and commercial, and industry interest is continuing to build. The benefits to patients can be seen through improved medical outcomes, while...

2008-09-18 06:00:40

Combating losses due to patent expiries has become a high priority for pharmaceutical companies. Investing in new drug delivery technologies is becoming a critical strategy for them to maintain a strong presence in this cut-throat market as they offer the potential to enhance the life cycle of established drugs. A number of drug delivery, pharmaceutical and biotechnology companies are allocating significant resources towards the development of novel drug delivery systems. Once a small...

2008-08-06 09:01:05

Cara Therapeutics has completed Phase I clinical trial for its second-generation, peripherally acting kappa opioid agonist, CR845, under development for the treatment of acute and chronic pain. The Phase Ia single-center clinical trial evaluated the safety, tolerability, pharmacokinetic profile, and pharmacological activity of CR845 in a double-blind, randomized, placebo-controlled, single escalating intravenous dose study in 54 healthy male and female volunteers. CR845 was shown to be safe...